BioCryst Pharmaceuticals
BCRX
177 hedge funds and large institutions have $898M invested in BioCryst Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 57 increasing their positions, 57 reducing their positions, and 15 closing their positions.
153% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 15
110% more capital invested
Capital invested by funds: $427M → $898M (+$471M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more funds holding
Funds holding: 154 → 177 (+23)
0% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 57
3.97% less ownership
Funds ownership: 72.26% → 68.29% (-4%)
16% less call options, than puts
Call options by funds: $10.5M | Put options by funds: $12.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$17.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.25M |
| 4 |
DM
Deerfield Management
New York
|
+$7.11M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$6.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$26.4M |
| 2 |
Millennium Management
New York
|
-$16M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11.2M |
| 4 |
Goldman Sachs
New York
|
-$6.01M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$5.41M |
BCRX Hedge Fund Activity: Q4 2020 in Review
177 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2020, worth a combined $898M — up 110% from $427M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new BCRX positions and 15 closed out — a net gain of 23 holders — while 57 added to existing stakes and 57 trimmed.
The largest buyer was Sarissa Capital Management, adding an estimated $17.1M. The largest seller was State Street, cutting an estimated $26.4M.
- 177 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2020, up from 154 in Q3 2020.
- Funds reported $898M of BioCryst Pharmaceuticals stock for Q4 2020, up 110% quarter-over-quarter.
- 38 funds opened new BioCryst Pharmaceuticals positions in Q4 2020 and 15 closed out, a net change of +23 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2020 was Sarissa Capital Management, an estimated $17.1M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2020 was State Street, an estimated $26.4M sold.
Based on aggregated 13F filings for Q4 2020.